cabazitaxel impacts sequencing strategies in prostate cancer
Published 4 years ago • 387 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:22
cabazitaxel improves rpfs in patients with mcrpc
-
4:50
card trial: cabazitaxel after ar-targeted therapy in mcspc
-
3:13
treatment options in metastatic prostate cancer
-
1:04
dr. grivas on potential combinations with cabazitaxel in prostate cancer
-
0:34
discussing the safety profile of cabazitaxel in mcrpc
-
6:37
case 2: sequencing therapy in mcspc
-
9:33
precision diagnostics and emerging treatment strategies
-
3:12
cabazitaxel (jevtana) for progressive metastatic prostate cancer after taxotere
-
1:33
dr. oh discusses the utility of cabazitaxel
-
7:09
cabazitaxel use in metastatic prostate cancer
-
1:37
cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer
-
4:59
an overview of sequencing in mcrpc
-
2:32
dr. sweeney on the optimal use of cabazitaxel
-
1:25:04
the prostate cancer therapeutic landscape: expert guidance on treatment sequencing and selection
-
1:11
dr. petrylak on sequencing agents in prostate cancer
-
0:34
jevtana’s toxicity profile makes it a good option in metastatic prostate cancer
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
0:16
cabazitaxel - jevtana in a nutshell